Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Mirikizumab in Moderate-to-Severe Plaque Psoriasis
jRCT2080223452Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of mirikizumab in plaque psoriasis (4 arms), sponsored by Eli Lilly and Company. Started Jan 2017; status: completed.
02
Drugs
mirikizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2080223452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223452.